CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric Cancer

NCT06667050 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

58

Enrollment

OTHER

Sponsor class

Conditions

Gastric Adenocarcinoma

Interventions

DRUG: Chemotherapy plus sintilimab and bevacizumab

Sponsor

West China Hospital